BD (Becton, Dickinson and Company) announced on May 21, 2025, new data from first-of-their-kind studies published in The Lancet Oncology and Cancer Medicine. These studies reveal that cancer patients in both hospital and outpatient settings face a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to non-cancer patients.
The research, led by the Cancer and AMR Consortium, found that AMR rates among key pathogens were 1 to 3 times higher overall in cancer patients, and up to 5 times greater for specific pathogen-source combinations in outpatient settings. For hospitalized cancer patients, AMR was 1.5 to 2 times more likely.
These findings highlight a critical need for enhanced infection prevention programs, focused antibiotic and diagnostic stewardship, and increased use of rapid diagnostic tools. The studies reinforce the importance of BD's diagnostic solutions in combating the rise of AMR, which contributes to approximately 4.7 million deaths per year globally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.